Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat

Journal of Neurochemistry

Volumn 90, Issue 5, 2004, Pages 1251-1257

  Stragier, Bart ^a   Sarre, Sophie ^a   Vanderheyden, Patrick ^a   Vauquelin, Georges ^a   Fournié Zaluski, Marie Claude ^b   Ebinger, Guy ^a   Michotte, Yvette ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b INSERM   (France)

Author keywords

Aminopeptidase A and N; Angiotensin II and IV; Extracellular dopamine; Insulin regulated aminopeptidase; Striatum

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 AMINO 4 METHYLSULFONYLBUTANETHIOL; 3 AMINO 4 MERCAPTOBUTYLSULFONIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II [3-8]; CANDESARTAN; DOPAMINE; ENZYME INHIBITOR; GLUTAMYL AMINOPEPTIDASE; INSULIN REGULATED AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; NALTREXONE; OPIATE ANTAGONIST; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CORPUS STRIATUM; DOPAMINE RELEASE; ENZYME INHIBITION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEMOGLOBINS; IMIDAZOLES; MALE; METHIONINE; MICRODIALYSIS; NALTREXONE; NARCOTIC ANTAGONISTS; PEPTIDE FRAGMENTS; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONIC ACIDS; TETRAZOLES; TIME FACTORS;

ANIMALIA;

EID: 4444300891     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02600.x     Document Type: Article

References (35)

1. 4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 276, 48623-48626.
2. Ardaillou R. and Chansel D. (1997) Synthesis and effects of active fragments of angiotensin II. Kidney Int. 52, 1458-1468.
3. Belcheva I., Ternianov A. and Georgiev V. (2000) Lateralized learning and memory effects of angiotensin II microinjected into the rat CA1 hippocampal area. Peptides 21, 407-411.
4. Brown D. C., Steward L. J., Ge J. and Barnes N. M. (1996) Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 118, 414-420.
5. Chansel D. and Ardaillou R. (1998) Active metabolites derived from angiotensin II. Nephrology 19, 427-432.
6. 3H]candesartan to intact cells and membrane preparations. Biochem. Pharmacol. 63, 1273-1279.
7. de Gasparo M., Husam A., Alexander W., Cat K. J., Chiu A. T., Drew M., Goodfriend T., Harding J. W., Inagami T. and Timmermans P. B. M. W. M. (1995) Proposed update of angiotensin receptor nomenclature. Hypertension 25, 924-927.
8. de Gasparo M., Catt K. J., Inagami T., Wright J. W. and Unger T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472.
9. Glamsta E. L., Meyerson B., Silberring J., Terenius L. and Nyberg F. (1992) Isolation of a hemoglobin-derived opioid peptide from cerebrospinal fluid of patients with cerebrovascular bleedings. Biochem. Biophys. Res. Commun. 184, 1060-1066.
10. 3H] losartan in the rat liver. Biochem. Pharmacol. 46, 1653-1660.
11. Handa R. K. (2000) Metabolism alters the selectivity of Angiotensin-(1-7) receptor ligands for Angiotensin Receptors. J. Am. Nephrol. 11, 1677-1386.
12. 4 receptor in human proximal tubule epithelial (HK-2) cells. J. Am. Soc. Nephrol. 12, 440-449.
13. 4 receptors: specificity and distribution. Kidney Int. 46, 1510-1512.
14. Herbst J. J., Ross S. A., Scott H. M., Bobin S. A., Morris N. J., Lienhard G. E. and Keller S. R. (1997) Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Am. J. Physiol. 272, E600-E606.
15. 4 receptor antagonist. Regulat. Peptides 67, 123-130.
16. Lee J., Chai S. Y., Mendelsohn F. A., Morris M. J. and Allen A. M. (2001) Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 40, 618-623.
17. Lee J., Mustafa T., McDowall G., Mendelsohn F. A. O., Brennan M., Lew R. A., Albiston A. A. and Chai S. Y. (2003) Structure-activity study of LVV-hemorphin-7: Angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J. Pharmacol. Exp. Ther. 305, 205-211.
18. Lew R. A., Mustafa T., Ye S., McDowall S. G., Chai S. Y. and Albiston A. L. (2003) Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J. Neurochem. 86, 344-350.
19. Mendelsohn F. A., Jenkins T. A. and Berkovic S. F. (1993) Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613, 221-229.
20. Moeller I., Lew R. A., Mendelsohn F. A., Smith A. I., Brennan M. E., Tetaz T. J. and Chai S. Y. (1997) The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. J. Neurochem. 68, 2530-2537.
21. Mustafa T., Hyung Lee J., Yeen Chai S., Albiston A. L., McDowall S. G. and Mendelsohn F. A. O. (2001) Bioactive angiotensin peptides: focus on angiotensin IV. J. Renin Angiotensin Aldosterone Syst. 2, 205-210.
22. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotactic Coordinates, 2nd Edn. American Press, San Diego.
23. Pederson E. S., Harding J. W. and Wright J. W. (1998) Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. Regul. Pept. 74, 97-103.
24. Reaux A., de Mota N., Zini S., Cadel S., Fournié-Zaluski M. C., Roques B. P., Corvol P. and Llorens-Cortes C. (1999) PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Neuroendocinology 69, 370-376.
25. Reaux A., Iturrioz X., Vazeux G., Fournie-Zaluski M.-C., David C., Roques B. P., Corvol P. and Llorens-Cortes C. (2000) Aminopeptidase A, which generate one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Biochem. Soc. Trans. 28, 435-440.
26. Saavedra J. M. (1999) Emerging features of brain angiotensin receptors. Regul. Pept. 85, 31-45.
27. Sarre S., Thorre K., Smolders I. and Michotte Y. (1997) Microbore liquid chromatography analysis of monoamine transmitters. Meth. Mol. Biol. 72, 185-196.
28. Song K., Allen A. M., Paxinos G. and Mendelsohn F. A. (1992) Mapping of angiotensin II receptors subtype heterogeneity in brain. J. Comp. Neurol. 316, 467-484.
29. Swanson G. N., Hanesworth J. M., Sardinia M. F. et al. (1992) Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul. Pept. 40, 409-419.
30. Thermos K., Radke J., Kastellakis A., Anagnostakis Y. and Spyraki C. (1996) Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study. Synapse 22, 209-216.
31. Van Heuven-Nolsen D. and Versteeg D. H. G. (1985) Interaction of vasopressin with the nigro-striatal dopamine system: site and mechanism of action. Brain Res. 337, 269-276.
32. Vauquelin G., Michotte Y., Smolders I., Sarre S., Ebinger G., Dupont A. and Vanderheyden P. (2002) Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J. Renin Angiotensin Aldosterone Syst. 3, 195-204.
33. Wright J. W. and Harding J. W. (1997) Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 25, 96-124.
34. Wright J. W., Stubley L., Pederson E. S., Kramar E. A., Hanesworth J. M. and Harding J. W. (1999) Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci. 19, 3952-3961.
35. Zini S., Fournié-Zaluski M. C., Chauvel E., Roques B. P., Corvol P. and Llorens-Cortes C. (1996) Identification of metabolic pathways of brain angiotensin II and III using aminopeptidase inhibitors: Predominant role of angiotensin III in the control of vasopressin release. Proc. Natl Acad. Sci. 93, 11968-11973.